Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.01 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | a small-molecule pocket | 0.60 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 2 Parkinson's papers of 198 | 0.85 |
| pathways Reactome | in no curated pathway | 0.00 |
No case: the score is under the bar. Receipt 10578
Sealed predictions
- NFKBIZ in dopamine neurons, braak+0.23 (p 0.545) → +0.26 (p 0.502)receipt 10585
Swarm cases
receipt 10585: NFKBIZ in dopamine neurons, braak
- power
- full sample +0.30 (p 0.228, n 18), 95% CI -0.20 to +0.67. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.24 (p 0.328, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.20 (p 0.418, n 18). could be the mix.
- skeptic
- leave-one-out range +0.21 to +0.41, sign flips 0; without severely affected donors +0.30 (p 0.228, n 18). fragile.
- cell type
- strongest in oligodendrocytes: +0.60 (p 0.0089, n 18) vs +0.30 in dopamine neurons. proposing oligodendrocytes.
- axis
- no measure beats "tracks Braak Lewy-body stage" for NFKBIZ in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up NFKBIZ · oligodendrocytes · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) +0.40 p 0.155 (needs p < 2.1e-4)
Receipts
loading the receipts